Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Vladimir Hanes

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Oncology and Therapy|December 18, 2020
The Totality of Evidence and Use of ABP 215, a Biosimilar to BevacizumabJerome Goldschmidt, Vladimir Hanes
Drugs & Aging|June 19, 2007
Drospirenone, a new progestogen, for postmenopausal women with hypertensionMadhavi Mallareddy, Vladimir Hanes, William B White
Oncotarget|February 5, 2019
Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilarsHans-Christian Kolberg, Gunter von Minckwitz, Vladimir Hanes
Cancer Chemotherapy and Pharmacology|August 6, 2021
A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjectsVladimir Hanes, Vincent Chow, Tina Stewart, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2017
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2017
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjectsVladimir Hanes, Vincent Chow, Nan Zhang, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2018
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjectsVladimir Hanes, Vincent Chow, Zhiying Pan, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2017
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.
Oncology and Therapy|January 11, 2021
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical ConsiderationsHans-Christian Kolberg, Georgia Savva Demetriou, Vladimir Hanes
Journal of the American Society of Hypertension : JASH|April 23, 2010
Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertensionWilliam B White, Vladimir Hanes, Madhavi Mallareddy, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Oncology and Therapy|December 18, 2020
The Totality of Evidence and Use of ABP 215, a Biosimilar to BevacizumabJerome Goldschmidt, Vladimir Hanes
Drugs & Aging|June 19, 2007
Drospirenone, a new progestogen, for postmenopausal women with hypertensionMadhavi Mallareddy, Vladimir Hanes, William B White
Oncotarget|February 5, 2019
Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilarsHans-Christian Kolberg, Gunter von Minckwitz, Vladimir Hanes
Cancer Chemotherapy and Pharmacology|August 6, 2021
A randomized, double-blind, single-dose study (LAVENDER) to assess the safety, tolerability, pharmacokinetics, and immunogenicity of a combined infusion of ABP 980 and pertuzumab in healthy subjectsVladimir Hanes, Vincent Chow, Tina Stewart, et al.
Cancer Chemotherapy and Pharmacology|September 3, 2017
A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.
Cancer Chemotherapy and Pharmacology|March 26, 2017
A randomized, single-blind, single-dose study evaluating the pharmacokinetic equivalence of proposed biosimilar ABP 980 and trastuzumab in healthy male subjectsVladimir Hanes, Vincent Chow, Nan Zhang, et al.
Cancer Chemotherapy and Pharmacology|October 1, 2018
A randomized, single-blind, single-dose study to assess the pharmacokinetic equivalence of the biosimilar ABP 215 and bevacizumab in healthy Japanese male subjectsVladimir Hanes, Vincent Chow, Zhiying Pan, et al.
Cancer Chemotherapy and Pharmacology|November 22, 2017
Correction to: A phase I, randomized, single-dose study evaluating the pharmacokinetic equivalence of biosimilar ABP 215 and bevacizumab in healthy adult menRichard Markus, Vincent Chow, Zhiying Pan, et al.
Oncology and Therapy|January 11, 2021
Totality of Evidence Supporting the Use of ABP 980, a Trastuzumab Biosimilar: Practical ConsiderationsHans-Christian Kolberg, Georgia Savva Demetriou, Vladimir Hanes
Journal of the American Society of Hypertension : JASH|April 23, 2010
Effects of the hormone therapy, drospirenone and 17-beta estradiol, on early morning blood pressure in postmenopausal women with hypertensionWilliam B White, Vladimir Hanes, Madhavi Mallareddy, et al.
Pageof 4